Analyze Deals at Sanofi-Aventis and Gain Valuable Insight into the Deal Making Process.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c43439) has announced the addition of PharmaDeals[R] Deal Making Spotlight Spotlight can refer to at least three types of lighting:
This title belongs to a series of reports dedicated to assisting companies in business development and deal making in the pharmaceutical & healthcare sectors. Published reports include: - Deal Making Spotlight on Pfizer Pfizer Incorporated (NYSE: PFE) is a major research-based pharmaceutical company, which ranks number two in sales The company is based in New York City. It produces the number-one selling drug Lipitor (atorvastatin, used to lower blood cholesterol); the oral antifungal - Deal Making Spotlight on Sanofi-Aventis - Deal Making Spotlight on GlaxoSmithKline GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a British based pharmaceutical, biological, and healthcare company. GSK is a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system (CNS), respiratory, - Deal Making Spotlight on Johnson & Johnson - Deal Making Spotlight on Novartis Novartis International AG (NYSE: NVS) is a multinational pharmaceutical company based in Basel, Switzerland that manufactures drugs such as diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / This report - "Deal Making Spotlight on Sanofi-Aventis" - details the deal making activities of Sanofi-Aventis, from 2000 up to and including the whole of 2005. If you are looking to partner with big pharma, this report is crucial to your deal making strategy. Each report is: Insightful - Presents and discusses the deal making activities of the company and its subsidiaries over a 5-year period. Key trends are identified, providing you with full information about your potential partner. Analytical analytical, analytic pertaining to or emanating from analysis. analytical control control of confounding by analysis of the results of a trial or test. - Analysis of deal making trends identifies: which phase each company deals at; how much each company pays for deals; what type of deals are made; what therapy areas are represented. This ensures you have the full information you need to plan the next step towards your deal. Comprehensive - The deal making profile covers all deals made by the company and its subsidiaries between 2000 and 2005. Commentary is supported by full lists of deals made as well as articles that provide in-depth in-depth adj. Detailed; thorough: an in-depth study. in-depth Adjective detailed or thorough: an in-depth analysis analysis of key deals made by the company in question SPOTLIGHT OVERVIEW SPOTLIGHT FOCUS Sanofi-Aventis Deal Making Subsidiaries DEAL MAKING Deal Making Overview Financial Information Partnering Companies Interest Areas Licensing Deal Focus R&D Deal Activity Marketing Deal Activity SANOFI-AVENTIS DEALS 2000-2005 FIELD DEFINITIONS Deal Types Product Types Interest Area Company Types SANOFI-AVENTIS DEALS 2000-2005 CATALOGUE CATALOGUE INDEX Index of Partnering Companies Index of Interest Areas APPENDICES ap·pen·di·ces n. A plural of appendix. Indications and Interest Areas Sanofi-Aventis article reprinted from the PharmaDeals[R] Review GUIDE TO PHARMADEALS[R] AGREEMENTS Figure 1 The proportion of the total annual revenues of the top 10 global pharmaceutical companies in 2004 generated by each company. Figure 2 The total number of deals made each year between 2000 and 2005 by Sanofi-Aventis compared to the average number of deals made by the top 10 global pharmaceutical companies. Figure 3 Deal making activities of Sanofi-Aventis between 2000 and 2005. Figure 4 Percentage of deals made by Sanofi-Aventis between 2000 and 2005 involving each deal type. Figure 5 Comparison of the total potential deal values based on deal type. Figure 6 Comparison of deal structure financial components based on deal type. Figure 7 Proportion of partnering companies by size and type. Figure 8 Number of deals involving each therapy interest area. Figure 9 Number of deals involving each technology interest area. Figure 10 In- in- word element [L.], in, within, or into. in- word element [L.], not. in- 1 or il- or im- or ir- pref. and out-licensing deals by product area. Figure 11 In- and out-licensing deals by phase of product development. Figure 12 Number of licensing deals by therapy interest area. Figure 13 Number of licensing deals by technology interest area. Figure 14 Number of R&D deals by therapy interest area. Figure 15 Number of R&D deals by technology interest area. Figure 16 Proportion of marketing deals by territory. Figure 17 Number of marketing deals by therapy interest area. For more information visit http://www.researchandmarkets.com/reports/c43439 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion